Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.62B P/E 43.28 EPS this Y 140.00% Ern Qtrly Grth 178.50%
Income 349.99M Forward P/E 22.11 EPS next Y -3.80% 50D Avg Chg 5.00%
Sales 2.01B PEG 1.53 EPS past 5Y 8.25% 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.58 EPS next 5Y 11.00% 52W High Chg -8.00%
Recommedations 2.10 Quick Ratio 4.08 Shares Outstanding 285.25M 52W Low Chg 37.00%
Insider Own 1.72% ROA 8.51% Shares Float 237.99M Beta 0.54
Inst Own 87.47% ROE 15.06% Shares Shorted/Prior 12.69M/11.79M Price 20.34
Gross Margin 96.06% Profit Margin 17.38% Avg. Volume 2,466,459 Target Price 27.70
Oper. Margin 43.37% Earnings Date Oct 28 Volume 4,906,656 Change 3.62%
About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc. News
12/20/24 The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
12/19/24 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
12/18/24 Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
12/17/24 Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says
12/12/24 SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
12/11/24 Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
12/09/24 Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
12/09/24 EXEL or INCY: Which Is the Better Value Stock Right Now?
12/09/24 AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
12/07/24 2 Biotech Stocks to Buy Hand Over Fist in December
12/06/24 Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?
12/04/24 Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?
12/04/24 Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders
11/29/24 Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?
11/29/24 Here's Why Exelixis (EXEL) is a Strong Momentum Stock
11/28/24 Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
11/27/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
11/27/24 ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
11/27/24 Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis
11/26/24 Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Sell 22.93 64,149 1,470,937 307,687 12/14/23
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Option 16.29 50,000 814,500 357,687 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Dec 13 Sell 23.01 25,000 575,250 533,345 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Nov 30 Sell 22.04 50,000 1,102,000 558,345 12/04/23
Aftab Dana CSO/EVP Disc & Trans.. CSO/EVP Disc & Trans Research Aug 30 Sell 22.47 4,600 103,362 399,943 09/01/23
MORRISSEY MICHAEL President and CEO President and CEO Aug 28 Option 15.31 360,000 5,511,600 945,496 08/30/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Option 14.74 120,000 1,768,800 631,631 08/07/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Sell 20.6 120,000 2,472,000 571,631 08/07/23
Haley Patrick J. EVP, Commercial EVP, Commercial Aug 03 Sell 20.67 30,553 631,531 285,467 08/07/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Sell 19.63 55,710 1,093,587 571,976 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Option 14.74 55,710 821,165 627,686 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Option 14.74 13,930 205,328 621,365 04/05/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Sell 20.01 38,930 778,989 582,435 04/05/23
WYSZOMIERSKI JACK L Director Director Mar 10 Sell 16.61 15,300 254,133 317,467 03/14/23
WYSZOMIERSKI JACK L Director Director Mar 10 Option 6.3 40,000 252,000 332,767 03/14/23
Garber Alan M Director Director Feb 21 Sell 17.49 40,000 699,600 31,417 02/23/23
Garber Alan M Director Director Feb 21 Option 6.3 40,000 252,000 71,417 02/23/23
FELDBAUM CARL B Director Director Feb 09 Sell 17.78 40,000 711,200 18,701 02/10/23
FELDBAUM CARL B Director Director Feb 09 Option 6.3 40,000 252,000 58,701 02/10/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Sell 17.37 25,000 434,250 254,414 02/08/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Option 4.2 25,000 105,000 279,414 02/08/23
MORRISSEY MICHAEL President and CEO President and CEO Jan 24 Option 4.2 100,000 420,000 440,655 01/26/23
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 4.2 20,000 84,000 430,958 12/16/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 15.88 20,000 317,600 410,958 12/16/22
POSTE GEORGE Director Director Nov 29 Sell 16.68 40,000 667,200 193,189 12/01/22
POSTE GEORGE Director Director Nov 29 Option 6.3 40,000 252,000 233,189 12/01/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Option 6.21 40,000 248,400 301,591 09/14/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Sell 17.94 40,000 717,600 261,591 09/14/22
Senner Christopher J. EVP and CFO EVP and CFO Aug 11 Option 6.21 225,000 1,397,250 670,882 08/12/22
Haley Patrick J. EVP, Commercial EVP, Commercial May 27 Sell 18.21 18,812 342,567 239,818 06/01/22
WILLSEY LANCE Director Director May 12 Option 3.13 40,000 125,200 464,415 05/13/22
WILLSEY LANCE Director Director May 12 Sell 19.65 40,000 786,000 424,415 05/13/22
WYSZOMIERSKI JACK L Director Director Apr 04 Option 3.13 40,000 125,200 279,888 04/06/22
WYSZOMIERSKI JACK L Director Director Apr 04 Sell 23 6,696 154,008 273,192 04/06/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Option 6.21 20,000 124,200 279,191 04/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Sell 22.72 20,000 454,400 269,191 04/04/22
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Mar 28 Sell 22 18,000 396,000 605,236 03/30/22
Garber Alan M Director Director Mar 01 Option 3.13 40,000 125,200 52,718 03/03/22
Garber Alan M Director Director Mar 01 Sell 21 21,301 447,321 31,417 03/03/22
Hessekiel Jeffrey EVP and General Coun.. EVP and General Counsel Feb 24 Sell 20 18,000 360,000 555,361 02/28/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 25 Sell 19.53 31,238 610,078 198,476 02/28/22
PAPADOPOULOS STELIOS Director Director Feb 22 Sell 19.56 84,515 1,653,113 1,220,036 02/24/22
FELDBAUM CARL B Director Director Feb 22 Option 3.13 20,000 62,600 28,521 02/24/22
FELDBAUM CARL B Director Director Feb 22 Sell 19.49 20,000 389,800 8,521 02/24/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Option 1.9 60,000 114,000 305,241 02/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Sell 17.91 60,000 1,074,600 245,241 02/04/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 6.21 47,500 294,975 410,672 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 17.44 47,500 828,400 363,172 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Option 6.21 47,500 294,975 458,740 10/15/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Sell 21.92 47,500 1,041,200 411,240 10/15/21